Busulfan in hematopoietic stem cell transplantation.
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.
Ciurea
Stefan O
SO
University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Andersson
Borje S
BS
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002066:Busulfan / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy; D019172:Transplantation Conditioning / Q000379:methods
D000970:Antineoplastic Agents; D002066:Busulfan